SAN DIEGO, Feb 14, 2007 (BUSINESS WIRE) -- Illumina (NASDAQ:ILMN) announced today that deCODE genetics, which operates the world's largest services facility offering Illuminasingle-nucleotide polymorphisms (SNP) genotyping services, hasreceived Illumina Certified Service Provider (CSPro) certification forInfinium(R) Genotyping.
Illumina, a San Diego-based company, provides next-generationtools for the large-scale analysis of genetic variation and function.deCODE, a global leader in applying human genetics to develop bettermedicine, has partnered with Illumina to provide unique, high-valuecontent for the Infinium Genotyping BeadChip, deliveringindustry-leading results for genotyping service customers.
"We chose Illumina because their data quality is the best in theindustry, and through our genotyping services we can in turn offerthis level of quality to our customers around the world. Our DiseaseMiner(TM) informatics suite further provides our customers with auser-friendly means of performing their own data management andstatistical analyses," said Jeff Gulcher, deCODE's Chief ScientificOfficer. "Receiving CSPro certification underscores deCODE'scommitment to providing the best and most comprehensive genotyping andanalytical solutions, speeding the discovery process for ourcustomers."
"deCODE is the largest laboratory to offer Infinium Genotypingservices, serving a growing list of customers in North America,Europe, and Asia. They are also the first laboratory outside of NorthAmerica to achieve Illumina CSPro certification for InfiniumGenotyping," said Karen Possemato, Illumina's Director of CorporateMarketing. "By contributing its unrivalled expertise in humangenetics, deCODE has helped to ensure that next generation InfiniumGenotyping products lead the industry in quality and content."
About Illumina CSPro
Illumina CSPro is a collaborative service provider partnershipdedicated to ensuring the delivery of the highest-quality dataavailable for genetic analysis applications. Illumina CSPros undergo arigorous two-phase certification process that includes minimum datageneration requirements, data certification and on-site audit of thefacility and processes. For more information about the CSPro program,please visit www.illumina.com/cspro.
About Illumina
Illumina (www.illumina.com) is developing next-generation toolsfor the large-scale analysis of genetic variation and function.
About deCODE Genotyping Services
deCODE operates the largest and most advanced high-throughputgenotyping facility in the world, supported by its renowned scientistsin genetics, robotics, statistics, and informatics. The company hasextensive experience in providing genotyping services and hasdeveloped powerful software tools to help its customers speed thediscovery process. deCODE provides a full range of services, includingInfinium platform SNP genotyping, with a capacity of 3 billion SNPsper month; microsatellite genotyping for genome-wide scans andfine-mapping; and DNA sample preparation. For more information, pleasevisit our website at www.decode.com/genotyping.
"Safe Harbor" Statement under the Private Securities LitigationReform Act of 1995: This release may contain forward-lookingstatements that involve risks and uncertainties. Among the importantfactors that could cause actual results to differ materially fromthose in any forward-looking statements are the costs and outcome ofIllumina's litigation with Affymetrix, our ability to effectivelyintegrate our recent acquisition of Solexa, Inc., Illumina's abilityto further develop and commercialize its BeadArray technologies and todeploy new gene expression and genotyping products and applicationsfor its platform technology, Illumina's ability to manufacture robustSentrix(R) arrays and Oligator(R) oligonucleotides, Illumina's abilityto scale and integrate CyVera technology, and other factors detailedin the Company's filings with the Securities and Exchange Commissionincluding its recent filings on Forms 10-K and 10-Q or in informationdisclosed in public conference calls, the date and time of which arereleased beforehand. Illumina disclaims any intent or obligation toupdate these forward-looking statements beyond the date of thisrelease.
Illumina, Inc.
Maurissa Bornstein, 858-332-4055
Public Relations Manager
mbornstein@illumina.com
or
deCODE genetics
Pernille Sorensen Baker, Ph.D., 354-570-2807
Director of Marketing, Genotyping Services
genotyping@decode.com
SOURCE: Illumina